← Human Trials & Peer-Reviewed Studies
VITamin D and OmegA-3 TriaL (VITAL) bone health ancillary study: clinical factors associated with trabecular bone score in women and men.
Plain-language guide to PMID 30022253 (2018): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 672 participants.
Key Facts
- PMID
- 30022253
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Goldman AL et al. (8 authors)
- DOI
- 10.1007/s00198-018-4633-3
- Registered trial
- NCT01747447
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
The researchers investigated the association of clinical variables with TBS at baseline in the bone health sub-cohort of the VITamin D and OmegA-3 TriaL (VITAL).
The researchers investigated whether TBS differs by sex, race, body mass index (BMI), and other clinical variables.
Who Took Part
According to the abstract, 672 participants were involved.
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
How the Study Was Run
The design is described as randomized and double-blind.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
In the VITAL: Effects on Bone Structure/Architecture ancillary study, effects of these interventions on bone will be investigated.
What Was Measured
Topics PubMed links to this paper include Absorptiometry, Photon, Aging, Bone Density, Cancellous Bone, Cholecalciferol, Dietary Supplements and Fatty Acids, Omega-3.
Author keywords: Fracture, Osteoporosis, SSRI, TBS and Trabecular bone score.
What This Means in Plain Language
The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 672 participants.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.